Onkologie. 2024:18(3):184-189 | DOI: 10.36290/xon.2024.034

Adjuvant therapy for renal cancer - update of KEYNOTE-564

Tomáš Büchler
Onkologická klinika, 2. LF UK a Fakultní nemocnice v Motole, Praha

Approximately 25% of patients with renal cell carcinoma (RCC) relapse after radical removal of the tumour. After several decades of unsuccessful clinical trials, significant progress has been achieved recently and a new standard of adjuvant treatment for patients with RCC and a higher risk of recurrence has been established. The randomized, double-blind KEYNOTE-564 trial demonstrated that pembrolizumab administered for 1 year after surgery significantly improved both recurrence-free and overall survival. The treatment is fully reimbursed and is the new standard in RCC therapy.

Keywords: renal carcinoma, adjuvant treatment, pembrolizumab, overall survival.

Accepted: June 18, 2024; Published: June 24, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T. Adjuvant therapy for renal cancer - update of KEYNOTE-564. Onkologie. 2024;18(3):184-189. doi: 10.36290/xon.2024.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dusek L, Muzik J, Kubasek M, et al. Epidemiology of Malignant Tumours in the Czech Republic [Internet]. Brno: Masaryk University; 2005 [cited 2023 May 3]. Available from: www.svod.cz.
    2. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009. Go to original source... Go to PubMed...
    3. Chowdhury N, Drake CG. Kidney Cancer: An Overview of Current Therapeutic Approaches. Urol Clin North Am. 2020;47(4):419-431. Go to original source... Go to PubMed...
    4. Larcher A, Fallara G, Rosiello G, et al. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. Eur Urol. 2020;78(3):321-326. Go to original source... Go to PubMed...
    5. Poprach A, Holanek M, Chloupkova R, et al. Cytoreductive nephrectomy and overall survival of patients with metastatic renal cell carcinoma treated with targeted therapy - data from the national renis registry. Cancers (Basel). 2020;12(10). Go to original source... Go to PubMed...
    6. Escudier BJ, Rini BI, Martini J-F, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. J Clin Oncol [Internet]. 2017;35(15_suppl):4508. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4508. Go to original source...
    7. Haas NB, Manola J, Dutcher JP, et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017;3(9):1249-1252. Go to original source... Go to PubMed...
    8. Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916-3923. Go to original source... Go to PubMed...
    9. Ryan CW, Tangen CM, Heath EI, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2023;402(10407):1043-1051. Go to original source... Go to PubMed...
    10. Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London, England). 2022;400(10358):1103-1116. Go to original source... Go to PubMed...
    11. Allaf ME, Kim SE, Master VA, et al. PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). J Clin Oncol [Internet]. 2021;39(15_suppl):TPS4596-TPS4596. Available from: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4596. Go to original source...
    12. Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2023;401(10379):821-832. Go to original source... Go to PubMed...
    13. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683-694. Go to original source... Go to PubMed...
    14. Choueiri TK, Tomczak P, Park SH, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;390(15):1359-1371. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.